Biblioteca Virtuale per la Salute – Piemonte – "Le biblioteche non si fanno…crescono" A. Birrell

Sfoglia per AUTORE
BALLANTI S
Collezione AOU Città della Salute di Torino

Items : 24

A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents. in Haematologica / Haematologica. 2024 May 1;109(5):1525-1534. doi: 10.3324/haematol.2023.284023.

2024
AOU Città della Salute di Torino

Mina R; Petrucci MT; Bonello F; Bongarzoni V; Saccardi R; Bertuglia G; Mengarelli A; Spadaro A; Lisi C; Curci P; Lemoli RM; Ballanti S; Floris R; Cupelli L; Tosi P; Olivieri A; Rota-Scalabrini D; Cangialosi C; Nozzoli C; Anaclerico B; Fazio F; Bruno B; Mancuso K; Corradini P; Milone G; Boccadoro M;

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. in Blood / Blood. 2024 Feb 15;143(7):592-596. doi: 10.1182/blood.2023022080.

2024
AOU Città della Salute di Torino

Paris L; Zambello R; Mancuso K; Gamberi B; Palmas AD; Gozzetti A; Cellini C; Ballanti S; Velluti C; Vincelli ID; Ronconi S; Pavone V; Grasso M; Ledda A; Oliva S; Corradini P; Morè S; Belotti A; Rota-Scalabrini D; Bertuglia G; D'Agostino M; Petrucci MT; Bruno B; Musto P; Gay F;

Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey. in International journal of antimicrobial agents / Int J Antimicrob Agents. 2023 Jun;61(6):106806. doi: 10.1016/j.ijantimicag.2023.106806. Epub 2023 Ap

2023
AOU Città della Salute di Torino

Trecarichi EM; Giuliano G; Cattaneo C; Ballanti S; Criscuolo M; Candoni A; Marchesi F; Laurino M; Dargenio M; Fanci R; Cefalo M; Delia M; Spolzino A; Maracci L; Bonuomo V; Busca A; Principe MID; Daffini R; Simonetti E; Dragonetti G; Zannier ME; Pagano L; Tumbarello M;

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. in The Lancet. Oncology / Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14.

2023
AOU Città della Salute di Torino

Grasso M; Zamagni E; Fioritoni F; Ballanti S; Cea M; Pescosta N; Pavone V; Ronconi S; Vincelli ID; Oddolo D; Capra A; Bertamini L; Cellini C; Gozzetti A; De Rosa L; Giuliani N; Aquino S; de Fabritiis P; Gamberi B; Palmas A; Rota-Scalabrini D; Paris L; Musto P; Mina R; Belotti A; Boccadoro M; Gay F;

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. in Hematological oncology / Hematol Oncol. 2022 Oct;40(4):704-715. doi: 10.1002/hon.3031. Epub 2022 Jun 1.

2022
AOU Città della Salute di Torino

Zamagni E; Bringhen S; Consoli U; Frigeri F; Pompa A; Tripepi G; Gamberi B; Gagliardi A; Gangemi D; Ballanti S; Martino M; Stocchi R; Cupelli L; Bonalumi A; Sgherza N; Vincelli D; Botta C; Mimmi S; Iaccino E; Vigna E; Mendicino F; Curci P; Uccello G; Criscuolo C; Belotti A; Cerchione C; Cascavilla N; Palumbo G; Pietrantuono G; et alii...

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. in European journal of haematology / Eur J Haematol. 2022 Mar;108(3):178-189. doi: 10.1111/ejh.13723. Epub 2021 Nov 9.

2022
AOU Città della Salute di Torino

Musso M; De Stefano V; Musto P; Rizzello I; Barone M; Farina G; Reddiconto G; Cangialosi C; Pia Falcone A; Frigeri F; Tripepi G; Ballanti S; Cascavilla N; Garibaldi B; Rocchi S; Pantani L; Mele A; Bruzzese A; Botta C; Vigna E; Antonia Martino E; Mele G; Donatella Vincelli I; Tacchetti P; Catalano L; Ria R; Rossi E; Derudas D; Galli M; et alii...

Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey. in Mycoses / Mycoses. 2022 Feb;65(2):171-177. doi: 10.1111/myc.13384. Epub 2021 Dec 3.

2022
AOU Città della Salute di Torino

Manetta S; Russo D; Melillo L; Dargenio M; Garzia M; Veggia B; Orciulo E; Zama D; Picardi M; Nadali G; Castagnola C; Decembrino N; Potenza L; Delia M; Prezioso L; Spolzino A; Fracchiolla N; Lessi F; Cattaneo C; Marchesi F; Candoni A; Fanci R; Ballanti S; Verga L; Conti A; Dragonetti G; Del Principe MI; Mancini V; Piedimonte M; et alii...

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials. in Frontiers in oncology / Front Oncol. 2022 Jul 18;12:890376. doi: 10.3389/fonc.2022.890376. eCollection 2022.

2022
AOU Città della Salute di Torino

De Stefano V; Musto P; Gamberi B; Curci P; Mimmi S; Rizzello I; Iaccino E; Barone M; Farina G; Reddiconto G; Cangialosi C; Falcone AP; Frigeri F; Tripepi G; Ballanti S; Cascavilla N; Garibaldi B; Rocchi S; Pantani L; Mele A; Botta C; Mendicino F; Bruzzese A; Martino EA; Vigna E; Mele G; Vincelli ID; Tacchetti P; Catalano L; et alii...

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. in Haematologica / Haematologica. 2021 Jan 1;106(1):291-294. doi: 10.3324/haematol.2019.241513.

2021
AOU Città della Salute di Torino

Gentile M; Specchia G; Derudas D; Galli M; Botta C; Rocco S; Conticello C; Califano C; Giuliani N; Mangiacavalli S; Attingenti E; Lombardo A; Brunori M; Rossi E; Antonioli E; Ria R; Zambello R; Di Renzo N; Mele G; Marcacci G; Musto P; Capalbo S; Cascavilla N; Cerchione C; Belotti A; Criscuolo C; Uccello G; Curci P; Vigna E; et alii...

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. in Blood cancer journal / Blood Cancer J. 2021 Dec 7;11(12):197. doi: 10.1038/s41408-021-00590-5.

2021
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Corradini P; Monaco F; Boccadoro M; Ballanti S; Offidani M; De Paoli L; De Sabbata G; Aquino S; Paris L; Grasso M; Belotti A; Cellini C; Tacchetti P; Zambello R; Musolino C; Cea M; Bonello F; Rota-Scalabrini D; Patriarca F; Capra A; Petrucci MT; Ciccone G; Liberati AM; Pescosta N; Bringhen S; Falcone AP; Mina R;

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

2021
AO Cuneo
AOU Città della Salute di Torino

Petrucci MT; Gamberi B; Zambello R; Palmas A; de Fabritiis P; Aquino S; Giuliani N; Capra A; D'Agostino M; Patriarca F; Spadano A; Cea M; Ballanti S; Ledda A; Grasso M; Zamagni E; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F; Corradini P; Cavo M; Boccadoro M;

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. in Haematologica / Haematologica. 2021 Apr 1;106(4):1079-1085. doi: 10.3324/haematol.2019.243428.

2021
AOU Città della Salute di Torino

Mina R; Bonello F; Petrucci MT; Liberati AM; Conticello C; Ballanti S; Musto P; Olivieri A; Benevolo G; Capra A; Gilestro M; Galieni P; Cavo M; Siniscalchi A; Palumbo A; Montefusco V; Gaidano G; Omedé P; Boccadoro M; Bringhen S;

Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis. in Mycoses / Mycoses. 2020 Sep;63(9):900-910. doi: 10.1111/myc.13130. Epub 2020 Jul 3.

2020
AOU Città della Salute di Torino

Posteraro B; De Carolis E; Criscuolo M; Ballanti S; De Angelis G; Del Principe MI; Delia M; Fracchiolla N; Marchesi F; Nadali G; Picardi M; Piccioni AL; Verga L; Candoni A; Busca A; Sanguinetti M; Pagano L; Posteraro B; De Carolis E; Criscuolo M; Ballanti S; De Angelis G; Del Principe MI; Delia M; Fracchiolla N; Marchesi F; Nadali G; Picardi M; Piccioni AL; et alii...

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. in Blood cancer journal / Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1.

2020
ASL Asti
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Romano A; Sonneveld P; Ria R; Musto P; Liberati AM; Offidani M; Giuliani N; Marchetti M; Mosca-Siez ML; de Fabritiis P; Gobbi M; Ballanti S; Cellini C; Grasso M; Monaco F; Ronconi S; Pescosta N; Di Lullo G; Capra A; Belotti A; Petrucci MT; Boccadoro M; Zambello R; Mina R;

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. in The Lancet. Haematology / Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.

2020
AOU Città della Salute di Torino

Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; et alii...

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. in Haematologica / Haematologica. 2020 Jul;105(7):1937-1947. doi: 10.3324/haematol.2019.226407. Epub 2019 Oct 3.

2020
ASL Torino 4
AOU Città della Salute di Torino

Boccadoro M; Larocca A; Falco P; Hájek R; Palumbo A; Marasca R; Cellini C; Petrucci MT; Tosi P; Gentile M; Baldini L; Santoro A; Aquino S; Poggiu M; Pavone V; Gazzera G; De Rosa L; Grasso M; Rota-Scalabrini D; Pezzatti S; Spada S; Ballanti S; Pescosta N; Paris L; D'Agostino M; Bringhen S;

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. in Haematologica / Haematologica. 2020 Jan;105(1):193-200. doi: 10.3324/haematol.2019.219139. Epub 2019 Jun 20.

2020
AOU Città della Salute di Torino
AOU Novara

Corradini P; Cavo M; Offidani M; Liberati AM; Sonneveld P; Hajek R; Nagler A; Ben-Yehuda D; Cascavilla N; Nozzoli C; Ballanti S; Galieni P; Patriarca F; Musto P; Musolino C; Ribolla R; De Paoli L; Di Raimondo F; Spada S; Boccadoro M; Gay F; Montefusco V;

Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. in Cancers / Cancers (Basel). 2019 Nov 5;11(11):1735. doi: 10.3390/cancers11111735.